Market Forecast News: Antibody Discovery Services Industry to Hit $3.54B by 2030
The report "Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030", is expected to reach USD 3.54 billion in 2030 from USD 1.90 billion in 2025, at a CAGR of 13.3% during the forecast period.
Browse 410 market data Tables and 60 Figures spread through 379 Pages and in-depth TOC on "Antibody Discovery Services Market - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/antibody-discovery-market-182887795.html
The antibody discovery services market is expanding due to the development of advanced formats like bispecific antibodies (bsAbs) and ADCs in clinical trials. Rising venture funding, strategic partnerships, and the integration of AI-driven, end-to-end service models are streamlining workflows, boosting efficiency, and accelerating innovation across the sector. However, the market also faces restraints such as the high cost and complexity of biologics discovery, which can limit accessibility and present challenges for smaller organizations seeking to enter or expand in this space.
The antibody engineering & optimization segment is expected to account for the highest growth rate in the antibody discovery services market, by type, during the forecast period.
The antibody discovery services market, by type, is segmented into target identification & validation, antibody engineering & optimization, antigen design & production, immunization & host management, and other services. The antibody engineering & optimization segment is expected to account for the highest CAGR throughout the forecast period. This service category encompasses a range of activities aimed at enhancing the therapeutic potential of antibody candidates, including affinity maturation, humanization, Fc engineering, and stability improvement. The prominence of this segment is linked to the demand for antibodies with improved efficacy, safety, and manufacturability profiles suitable for clinical development. Pharmaceutical and biotechnology companies frequently utilize engineering and optimization services to refine initial antibody leads generated through screening platforms, ensuring candidates can progress successfully into preclinical and clinical stages. Service providers in this area employ advanced computational modeling, high-throughput screening, and structure-guided design to support optimization workflows. The widespread application of these techniques across therapeutic areas such as oncology, immunology, and infectious diseases established antibody engineering and optimization as the fastest-growing segment in the antibody discovery services market during the forecast period.
The monoclonal antibodies segment accounted for the largest share of the molecule segment in 2024.
Based on molecule, the antibody discovery services market is segmented into monoclonal antibodies, polyclonal antibodies, and other molecules. In 2024, the monoclonal antibodies segment held the largest share of the market while also being the fastest growing segment. The segment is expected to grow due to the widespread application across a broad range of therapeutic areas, including oncology, autoimmune disorders, and infectious diseases. Monoclonal antibodies are established as a major class of biologics due to their target specificity and consistent performance in clinical development, making them a core focus of discovery pipelines. Service providers support this demand through platforms that enable immunization, screening, and engineering to generate high-quality monoclonal antibody candidates. The continued clinical and commercial success of monoclonal antibodies has reinforced their central role, with pharmaceutical and biotechnology companies prioritizing these molecules in research and development programs. The extensive infrastructure and expertise for monoclonal antibody discovery further strengthened their prominence, making this category the leading molecule type in the antibody discovery services market.
By region, the Asia Pacific is expected to experience the highest CAGR in the antibody discovery services market throughout the forecast period.
Asia Pacific was the fastest-growing segment during the forecast period. Growth in the region was supported by the expansion of pharmaceutical and biotechnology activities, particularly in countries such as China, India, South Korea, and Japan. Increasing investments in research and development, the establishment of specialized antibody discovery facilities, and the availability of skilled scientific talent contributed to the rising demand for these services. Governments and private organizations in the region have increased funding for biologics research, creating opportunities for service providers to expand operations and partnerships. The lower cost of conducting research and clinical studies in several Asia Pacific countries also encouraged outsourcing by global pharmaceutical companies. In addition, the rising prevalence of chronic diseases and a growing pipeline of antibody-based therapeutics supported demand. These factors collectively positioned Asia Pacific as the fastest-growing regional market for antibody discovery services.
Some of the leading players in the market include Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), and Aragen Life Sciences Ltd. (India) among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Antibody Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
